Design and synthesis of 3,5-disubstituted boron-containing 1,2,4-oxadiazoles as potential combretastatin A-4 (CA-4) analogs

被引:20
作者
Das, Bhaskar C. [1 ]
Tang, Xiang-Ying [2 ]
Rogler, Patrick [2 ]
Evans, Todd [1 ]
机构
[1] Cornell Univ, Dept Surg, Weill Cornell Med Coll, New York, NY 10065 USA
[2] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA
关键词
3,5-Disubstituted 1,2,4-oxadiazole; Combretastatin A-4; Bioisosteres; Vascular disrupting agent; Tubulin; Boron-containing CA4 compound; VASCULAR DISRUPTING AGENTS; ANTINEOPLASTIC AGENTS; ANTICANCER AGENTS; TUBULIN POLYMERIZATION; OXADIAZOLE DERIVATIVES; ANTITUMOR-ACTIVITY; COMBRETUM-CAFFRUM; CELL-LINES; INHIBITION; DISCOVERY;
D O I
10.1016/j.tetlet.2012.02.110
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
We have designed and synthesized a small library of 3,5-disubstituted-1,2,4-oxadiazole containing combretastatin A-4 (CA-4) analogs. Our objective is to increase the efficacy of the CA-4 as an anti-tubulin and antimitotic agent by substituting the cis-alkene bond with one of its bioisosteres, the 1,2,4-oxadiazole ring. We also modified the substituents attached to both of the phenyl rings (ring A and B in Fig. 1) of CA-4 for the purpose of diversifying our analogs based on SAR. These compounds were synthesized via a coupling reaction between an amidoxime and a carboxylic acid in DMF solvent, with HOBt as a base, and utilizing EDCI as a coupling reagent. Using this protocol, we synthesized a small library of 10 compounds with moderate to good yields. A detailed biological study is currently undergoing in our laboratory to evaluate the activity of these compounds. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3947 / 3950
页数:4
相关论文
共 45 条
  • [1] Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
    Bedard, Philippe L.
    Di Leo, Angelo
    Piccart-Gebhart, Martine J.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (01) : 22 - 36
  • [2] Chaplin DJ, 2006, CURR OPIN INVEST DR, V7, P522
  • [3] Chawla R, 2010, ACTA POL PHARM, V67, P247
  • [4] Design and synthesis of novel pinacolylboronate containing combretastatin 'antimitotic agent' analogues
    Das, Bhaskar C.
    Mahalingam, Sakkarapalayam M.
    Evans, Todd
    [J]. TETRAHEDRON LETTERS, 2009, 50 (25) : 3031 - 3034
  • [5] Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit?
    Gaukroger, K
    Hadfield, JA
    Lawrence, NJ
    Nolan, S
    McGown, AT
    [J]. ORGANIC & BIOMOLECULAR CHEMISTRY, 2003, 1 (17) : 3033 - 3037
  • [6] GRIGGS J, 2001, LANCET ONCOL, V2, P81
  • [7] Groziak MP, 2000, PROG HET CH, V12, P1, DOI 10.1016/S0959-6380(00)80003-3
  • [8] Haar E.T., 1996, BIOORGAN MED CHEM, V4, P1659
  • [9] Novel B-ring modified combretastatin analogues: Syntheses and antineoplastic activity
    Hatanaka, T
    Fujita, K
    Ohsumi, K
    Nakagawa, R
    Fukuda, Y
    Nihei, Y
    Suga, Y
    Akiyama, Y
    Tsuji, T
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (23) : 3371 - 3374
  • [10] Vascular disrupting agents in clinical development
    Hinnen, P.
    Eskens, F. A. L. M.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 96 (08) : 1159 - 1165